Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Has anyone seen any news to warrant the recent drop?
My take is that, given no news, it's simply a very volatile trading stock and should bounce up from the .50s but that's just an opinion and we know what opinions are worth!
Kind regards,
Minding
Levon Provides Update on TSX Listing
Marketwired Levon Resources Ltd.
20 minutes ago
????
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jul 7, 2015) - Levon Resources Ltd. (LVN.TO)(LVNVF)(LO9.F)(LO9.F) ("Levon" or the "Company") wishes to update securityholders on the expected listing date (the "Listing") of the new class of common shares (the "New Levon Shares") of Levon and the common shares (the "Spinco Shares") of 1027949 B.C. Ltd. ("Spinco") on the Toronto Stock Exchange ("TSX") following completion of the previously announced plan of arrangement (the "Arrangement") involving SciVac Ltd., Levon and Spinco, which is expected to complete on July 9, 2015.
Upon completion of the Arrangement, the current Levon common shares (the "Old Levon Shares") will continue to trade on the TSX under the trading symbol "LVN" for 3 business days, but will represent rights of shareholders to receive New Levon Shares and Spinco Shares immediately upon Listing. Assuming completion of the Arrangement on July 9, 2015 and subject to the receipt of final approval of the TSX, the New Levon Shares and the Spinco Shares are expected to commence trading on the TSX on or about July 14, 2015 under the trading symbols "VAC" and "LVN", respectively. The Old Levon Shares are expected to cease to be listed for trading on the TSX on or about the close of business on July 13, 2015.
Upon completion of the Arrangement Levon will change its name to "SciVac Therapeutics Inc." and Spinco will change its name to "Levon Resources Ltd.".
For details of the Arrangement, please see Levon's management information circular dated May 1, 2015 and Levon's press release dated March 20, 2015, both of which have been filed on Levon's profile on SEDAR at www.sedar.com.
About Levon Resources Ltd.
Levon is a gold and precious metals exploration Company, exploring the Company's 100% owned flagship Cordero bulk tonnage silver, gold, zinc, and lead project near Hidalgo Del Parral, Chihuahua, Mexico.
ON BEHALF OF THE BOARD
Ron Tremblay, President and Chief Executive Officer
Safe Harbour Statement - This news release contains "forward-looking information" and "forward-looking statements" (together, the "forward looking statements") within the meaning of applicable securities laws and the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements, include, but are not limited to, statements regarding the completion of the Arrangement, the Listing and the trading of the Old Levon Shares and New Levon Shares on the TSX and are made as of the date of this news release. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the future circumstances, outcomes or results anticipated in or implied by such forward-looking statements will occur or that plans, intentions or expectations upon which the forward-looking statements are based will occur. While we have based these forward-looking statements on our expectations about future events as at the date that such statements were prepared, the statements are not a guarantee that such future events will occur and are subject to risks, uncertainties, assumptions and other factors which could cause events or outcomes to differ materially from those expressed or implied by such forward-looking statements.
Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.
Contact:
Levon Resources Ltd.
Investor Relations
604-682-2991
Levon Resources Ltd.
Main Office
778-379-0040
From Yahoo
It's of course difficult to know anything since they communicate very little. Unless one believes in miracles, their progress most likely parallels other biotechs.
Most importantly they presented at a Jeffries conference on June 4, 2015 (http://finance.yahoo.com/news/cocrystal-pharma-present-jefferies-2015-132731364.html) and look at what the stock did that day and since.
Kind regards,
Minding
Thanks. This does indeed appear to be a golden opportunity and one needn't rush in. I'll pick my time after the energy company and SciVac split up.
Minding
Ford: For those interested, here's an article and its link.
As for Ford, it's John H. (http://seekingalpha.com/author/john-h-ford). He's written 36 SA articles, many focused on Opko but also MusclePharm and Biozone (now Cocrystal). There are no statistics regarding his track record, but like many of us he appears to have been successful with OPK, MSLP, BZNE/COCP. However to read the juicy stuff he evidently writes, you have to subscribe for $300/month (https://secure.seekingalpha.com/pro/checkout/1876791?notice=pro).
As with any investing information, do your own DD.
Kind regards,
Minding
=============
From http://finance.yahoo.com/news/mabvax-receives-coverage-5-near-165200257.html
MabVax Receives Coverage with a $5 Near-Term Price Target Based on Upcoming Catalysts
Accesswire
July 1, 2015 12:52 PM
????
NEW YORK, NY / ACCESSWIRE / July 1, 2015 / Market Exclusive announces that today, John H. Ford, who primarily focuses on undervalued situations has initiated coverage in MabVax Therapeutics (OTCQB:MBVX).
Ford explains that Mabvax is attractive due to multiple potential upcoming catalysts. According to the report, "This is an exciting time for MabVax (OTCQB:MBVX), shareholders because the company's share price could rise from $2 to over $5 in the next few weeks based on MabVax's extreme level of undervaluation and 2 imminent catalysts."
Today Mabvax is trading on strong volume based on the continued investment by Dr. Phillip Frost and Opko (OPK), which has the shares trading slightly higher.
The report can be found at http://seekingalpha.com/author/john-h-ford/instablog
Some of the highlights from Ford's research:
- MabVax is completely undiscovered by Wall Street and would be undervalued even if the share price doubled.
- Dr. Phillip Frost and Opko (NYSE OPK) just invested in MabVax and given Dr. Frost's track record, MabVax could be another home run trade.
- In neuroblastoma trials MabVax demonstrated its drug is almost twice as effective as the standard of care.
- The Cancer Immunotherapy Index has risen almost 50% this year and MabVax is a major contender in that sector.
About Market Exclusive
Market Exclusive is a financial portal geared to engaging discussion on current financial topics. Market Exclusive is not an investment advisor.
The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
SOURCE: Market Exclusive
ADR Offering Prospectus: https://www.bamsec.com/filing/119312515230004?cik=1552795
Kind regards,
Minding
jfk, without a link (Who is John Ford? This guy? http://seekingalpha.com/author/john-ford/articles) and more details it's not possible to evaluate your statement.
Kind regards,
Minding
With a 782M market cap COCP seems to me to have gotten ahead of itself. If accurate, I think a reverse split will only temporarily raise the price because their work doesn't warrant it yet.
I sold half my shares and if this pops up will undoubtedly sell the remainder unless some piece of news changes my mind.
Kind regards,
Minding
I took profit until shares are separated.
As long as Frost is involved this will be a good bet but remember BZNE/COCP? The stock dropped quite a bit for a bit around and after the time of the conversion.
The danger here is losing out to momo traders but since I'm not one I'm ok with that. And I've already profited handsomely.
Kind regards,
Minding
Not I. TIK appears to me to have revealed the range in which it will trade for awhile. I don't expect much from this until mid-2016. Of course, as SSK says, I could be wrong!
Kind regards,
Minding
That's the thing I like about Fibonacci, Wave Theory, technical indicators, etc. They speak for/about the momo guys which enhances all that fundamental preparation.
Momo's appear to have taken BSQR too high too fast, which of course is what they do. This happened with RMTI to a lesser extent -- popped on the 25th and slipped back -- and BLRX may be in this process, though it seems a little more controlled at the moment. The thing about too-far-too-fast is when these stocks settle afterwards, they often settle at a reasonable valuation. My guess with BSQR is that it won't go shooting back up soon ... unless a catalyst is pending.
Minding
hweb, I subscribe to Fibonacci %s with retracements like this. Depending upon how it closes today, I'm looking for BSQR to dip below 6.50; possibly fairly close to 6.05-6.10 and bounce back up to the 6.50 area.
Thanks for highlighting this.
Kind regards,
Minding
Fits your thinking Steve. Thanks.
George
Great! Thanks.
MInding
From the Management Circular:
While certain matters, such as the timing of the receipt of required regulatory approvals, are beyond the control of Levon, if the resolution approving the Arrangement is passed by the requisite majority at the Meeting, and the other conditions to closing are satisfied, it is anticipated that the Arrangement will be completed and become effective on or about June 5, 2015.
-----------------
http://finance.yahoo.com/news/levon-obtains-final-order-plan-190105020.html
-----------------
Nothing beyond this point is clear to me. To satisfy your curiosity, ou can read the Management Circular at http://www.sedar.com
Kind regards,
Minding
For those not familiar with LVNVF, Frost got very cute with his strategy involving the privately held SciVac, an Israeli biotech. He wanted to take SciVac public so he secured a Canadian silver mining company in order to have a ticker. (If you go to Levon's website while it still is a mining website -- http://www.levon.com/s/Home.asp -- be not concerned.)
Next he merged Levon Resources, the mining company, and SciVac, the biotech. Then he filed a Canadian Business Corporation Act 'Arrangement' to split up the mining business and the biotech business, giving shares of both to Levon shareholders; he received shareholder approval at a recent Special Meeting.
From the Management Circular at Sedar: "Levon Shareholders will hold 100% of the issued and outstanding Spinco Shares and 31.6% of the issued and outstanding New Levon Shares, with the former SciVac Securityholders [that would be Frost and friends] holding the remaining 68.4% of the issued and outstanding New Levon Shares."
Once this is accomplished, we'll be off to the races.
Kind regards,
Minding
Agree with hweb2 on the backlog issue. Additionally if I heard correctly on the CC the prospects of their major catalyst (in my opinion) making a difference won't begin to happen in earnest for 1 1/2 years. That has dimmed my enthusiasm. I want to read the CC transcript or relisten.
Kind regards,
Minding
I wasn't willing to hold into the announcement and CC. Sold at 6.20; bought back at 5.30 ... possibly too early since Mode 5 sales won't pickup until 2017 according to the CEO on the CC.
Kind regards,
Minding
Right, TF. I sold out last night. Good move. But bought at 5.30 ... too early.
Kind regards,
Minding
I hadn't realized the pressure on countries to upgrade to Mode 5 will begin in 2017.
Still listening.
Kind regards,
Minding
Key point on the CC: The pressure on countries to upgrade to Mode 5 will begin in 2017.
Still listening.
Kind regards,
Minding
pmony5, to clarify, EPS was $.11 and non-GAAP Adjusted EBITDA was $0.21 for the quarter. For the year, non-GAAP Adjusted EBITDA was $0.17. Looking good.
Thanks for this one.
Kind regards,
Minding
Huge potential but not anytime soon -- a year or more. And the market didn't like the report ... or, as I suspect, a secondary is in the works.
Kind regards,
Minding
MediciNova Is An Excellent Opportunity In The Biotech Space
Jun. 22, 2015 2:34 PM ET | About: MediciNova, Inc. (MNOV), Includes: IPF
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)
From http://seekingalpha.com/article/3275225-medicinova-is-an-excellent-opportunity-in-the-biotech-space?ifp=0
Summary
MediciNova is focusing its efforts on MN-166 and MN-001.
MN-166 is being developed in multiple indications, while MN-001 is being developed in NASH and IPF.
MediciNova looks undervalued based on the potential of its pipeline.
MediciNova Inc. (NASDAQ:MNOV) is a small cap biotech company based in La Jolla, California-based company, with multiple products in its pipeline. The company is currently focusing its efforts on the development of MN-166 or Ibudilast in multiple indications and MN-001 for the fibrotic diseases such as NASH and PF. Recently, MN-166 was granted an Orphan Drug Designation by the FDA for Krabbe Disease. MN-001 has also been granted an Orphan Drug Designation for the treatment of idiopathic pulmonary fibrosis (NYSEARCA:IPF). MNOV has two more products in its pipeline. Despite a robust pipeline, MNOV only has a market capitalization of under $100 million. Even if MNOV is successful in developing and bringing to market just one of its two lead products in one or two indications, there could be tremendous upside.
MN-166
MediciNova is currently focusing its efforts on the development of MN-166 and MN-001. MN-166 is an inhibitor of macrophage migration inhibitory factor (MIF) and certain phosphodiesterases (PDEs). It has been in use for more than two decades in Japan and Korea for the treatment of asthma and post-stroke dizziness. MNOV licensed MN-166 from Kyorin Pharmaceuticals in 2004 and is developing it for the treatment of primary progressive and secondary progressive multiple sclerosis (NYSE:MS), amyotrophic lateral sclerosis (ALS) and drug dependence.
Around 2.3 million people globally are affected by MS, according to the National Multiple Sclerosis Society. While there are existing therapies available for MS, there is a need for a safe and effective therapy for primary and secondary progressive MS. Following promising results from Phase 2a trial in primary progressive and secondary progressive MS, investigators from NeuroNEXT commenced evaluation of MN-166 in both the conditions in the U.S. NeuroNEXT is a NIH-funded Phase clinical trial network. Recruitment and enrollment of patients in the clinical trial began in late 2013. In May, MNOV announced that the trial was fully enrolled. The company expects the trial to be completed in 2017.
MNOV also has an ongoing trial of MN-166 in ALS, which is being conducted by Carolinas Neuromuscular/ALS-MDA Center at Carolinas Healthcare System Neurosciences Institute. The trial will be evaluating several efficacy endpoints in addition to monitoring the safety and tolerability of MN-166 60 mg/day versus placebo when administered in combination with riluzole. In February, MNOV enrolled 30 of the 60 patients planned for the trial. In April, MNOV announced positive interim safety data from the clinical trial.
MN-166 is also being evaluated in methamphetamine-dependent users. Investigators at UCLA commenced a Phase 2 trial in MA-dependent users in 2013 after obtaining grant funding from NIDA. In February 2013, MN-166 was also granted a Fast Track Designation by the FDA for the treatment of MA dependence. UCLA has also received funding from the NIAAA to commence a Phase 2a study to evaluate MN-166 in a sample of 24 non-treatment seeking individuals with either alcohol abuse or dependence.
Investigators at Columbia/NYSPI have initiated at NINDA-funded Phase 2a clinical trial of MN-166 for the treatment of prescription opioid dependency. Last year, MNVO announced positive interim results from this study.
MN-166 has also been granted an Orphan Drug Designation by the FDA for the treatment of Krabbe disease, a rare genetic degenerative disorder. Currently there is no cure for the disease and it is fatal in general before two years of age. The company has previously opened an Investigational New Drug (NYSE:IND) application with the Division of Neurology products for MN-166.
MN-001
MN-001 is a novel, orally bioavailable small molecule compound. MNOV completed a pre-clinical study assessing the drug's potential clinical efficacy for the treatment of NASH. NASH is a common liver disease, resembling alcoholic liver disease but is found in people who do not drink or drink little alcohol. NASH affects 2%-5% of the American population, according to the U.S. National Digestive Diseases Information Clearinghouse. NASH can lead to liver cirrhosis.
NASH is being seen as a multi-billion opportunity, given its prevalence and significant unmet medical need. Several companies are currently focusing on NASH treatment. The NASH treatment market could evolve into a multi-billion opportunity, although it will be highly competitive. But the FDA has granted MN-001 a Fast Track Designation for the treatment of patients with NASH with fibrosis.
MN-001 also has an Orphan Drug Designation for the treatment of IPF, which was granted by the FDA in October 2014. In February, the FDA approved the protocol for Phase 2 trial of MN-001 in IPF.
MNOV Looks Undervalued
MediciNova's pipeline has huge potential. However, this is not yet reflected in the company's share price. MNOV shares are currently trading around $4, although their performance this year has been impressive. Year-to-date, MNOV has gained more than 30%.
Each of the indications that MNOV is targeting with its MN-166 and MN-001 is represents a major opportunity. The top five drugs for the treatment of MS had each had sales of more than a billion dollars in 2013. But as I noted that there is still a need for safe and effective treatment options and MN-166 has the potential to emerge as one. Even if MN-166 achieves $500 million in sales for MS, which is a very conservative estimate, then MNOV could have significant upside. MA dependence is once again a major opportunity for MNOV. According to data from Rand Corporation, the economic burden of MA dependence is around $23.4 billion and currently there are no available treatments.
MN-001 in NASH also represents a multi-billion dollar opportunity for MNOV. Many analysts believe that the NASH treatment market could become even bigger than the hepatitis C treatment market, which is expected to exceed $15 billion by the end of 2022. Although the NASH treatment market is expected to be extremely competitive, MN-001 could generate significant sales for MNOV even if the company is able to gain a small portion of this market.
The only issue with MNOV is when its drugs will reach the market. I believe that this is the reason why investors are keeping away from this opportunity. MNOV's clinical trials for MN-166 and MN-001 are investigator-sponsored and funded with or without government grants. This means that the company has not been able to advance its pipeline as quickly as investors would have liked. Of course, this is part of MNOV's strategy of advancing its pipeline through non-dilutive financing. However, MNOV plans to enter into strategic alliances with major pharmaceutical companies once it enters into late-stage product development. This could accelerate the development and commercialization process.
Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
Alan, I don't think they are asking that question.
I don't believe as researchers the need for investor support is 'real' to them. 623M shares isn't real to them. They have been weened on grants and have a grant frame of mind. They will be forced into the reality of shareholder-management discussion after things are working ... or if their work takes too long to come to fruition.
George
We're not in disagreement Alan about the need and the proper steps to take. I'm saying I don't see them doing it because they don't want the interference at this stage.
George
For better or worse Alan, I think these guys want to be locked and loaded before they add independent directors (or uplist, for that matter).
Kind regards,
Minding
The Bear Case On Rockwell Appears Gutted
Jun. 17, 2015 4:18 PM ET | 7 comments | About: Rockwell Medical, Inc. (RMTI), Includes: BAX, CMS, FMS
Disclosure: I am/we are long RMTI. (More...)
Summary
Rockwell has addressed every objection of short sellers over the past two years.
Triferic and Calcitriol expected to generate revenues by year end.
Insiders holding firm even as their stock's price and short interest have risen substantially.
Shares of Rockwell Medical (NASDAQ:RMTI) are (finally) attempting a breakout after trading sideways to down for over a year. The only recent news for the company seems small, but the increased volume behind its stock's bullish price action shows promise that investors may be overlooking the false specter RMTI's large short-interest is casting, and buying into the company's very apparent short and long-term appreciation potential.
Rockwell Medical is one of the two major suppliers of chemicals used in dialysis (dialysates) in the U.S. market. The other is Fresenius Medical Care (NYSE:FMS). Rockwell scored a big win with its dialysates business last October in the form of a distribution agreement with and investment from Baxter International (NYSE:BAX). The company is also busy preparing for the commercial launch of Calcitriol and Triferic, two drugs that both received FDA approval recently. Calcitriol is a low-cost generic vitamin D drug used in dialysis. Triferic is a potentially disruptive drug that changes the way anemia is treated in dialysis patients.
The most recent news on Rockwell is that the Centers for Medicare and Medicaid Services (NYSE:CMS) has granted a unique product reimbursement code for Rockwell's potentially disruptive Triferic drug. Short sellers have been wrong about many aspects of Rockwell during our nearly two years in the stock, and quite soundly so about Triferic-which is creating a new treatment paradigm for hemodialysis patients rather than simply competing with an existing drug. The CMS's code is yet another step towards the launch of Triferic.
The real surprise is that Rockwell's stock hasn't already traded more strongly since Triferic gained FDA approval in January. The average of analysts' expectations right now are for Rockwell's revenues to increase 27% this year, to $69 million, and nearly 70% next year, to $115 million. That's impressive, but these estimates are most instructive for their large range.
The low-end of revenue expectations for this year are a mere $56 million!? That's just a 3.7% increase from last year's sales-and is absolutely reflecting the bear case that neither Calcitriol nor Triferic is commercially viable. With over 25% of RMTI's float shorted, this case has quite a few advocates.
We have nothing against short sellers. But if the bear case had any legitimacy last year, it now seems obviously contrived after both Calcitriol and Triferic gained FDA approvals, and Rockwell solidified funding and a partnership with Baxter International. Even Rockwell's Q1 sales growth of 7.1% year-over-year makes that low-end revenue estimate for 2015 seem more based on an agenda than an honest calculation. (See our November 12, 2014 article on RMTI for more background on Rockwell's struggle with the bears.)
Management made clear in its Q1 conference call that feedback on Triferic from physicians and providers "continues to be very positive". They also expect both Calcitriol and Triferic to launch in July or August this year. Executives faith in their new products is also reflected in the continuing bullish-leaning insider trading profile for RMTI.
There appeared to be some disappointment on the Q1 conference call from questioners that Calcitriol wasn't launching by the end of Q2, but we hold no concerns about the time line. We've been waiting nearly two years for RMTI to reflect the full promise of the new drugs that were part of our initial investment thesis.
We don't think ourselves too greedy to believe that we should already have a much higher gain in RMTI given Rockwell's FDA approvals. The Baxter funding and partnership is just more good news besides that hasn't been figured into Rockwell's stock price. If it takes another quarter-or even two-for revenues from Calcitriol and Triferic to smite the bear case once and for all, we're fine with that. And we'd be very surprised at this point if the bear case on RMTI was not invalidated this year.
Rockwell is an established healthcare firm that is debt-free with $1.65 per share in cash on its balance sheet. Its two new products are set to add significantly to its top line beginning in Q3 or Q4 of this year, with leveraged affects expected for the company's earnings in coming years. We continue to view RMTI as a compelling long.
While shorts could yet cause more shenanigans in RMTI's trading, the stock's latest surge is showing that bulls are also emboldened. Unsurprisingly, RMTI is finding resistance at its past all-time high of around $15. But with the momentum behind Rockwell's product launches clearly on the side of the bulls, we fully expect RMTI to break out to new highs later this year.
From http://seekingalpha.com/article/3265915-the-bear-case-on-rockwell-appears-gutted?ifp=0
Back to the base we go. Clearly the trial approval is perceived by the market as the beginning of the trial and not the end. True enough. I still look for the price to normalize just under a dollar.
Minding
Another ... http://ih.advfn.com/p.php?pid=nmona&article=67312343&xref=newsalert
If I read this correctly, only 5M of the 16M are potentially dilutive.
"The Selling Securityholders may sell some, all or none of their shares. We do not know how long the Selling Securityholders will hold the shares before selling them, and we currently have no agreements, arrangements or understandings with the Selling Securityholders regarding the sale or other disposition of any of the shares. The shares covered hereby may be offered from time to time by the Selling Securityholders."
I note NBY has a small float.
Minding
Indeed! They are on track.
I look for it to remain between .90 and 1.00 however I'd be delighted if it gives us more.
Kind regards,
Minding
CC today should give us more information.
Minding
Couch,
The first part of my message read "... or there's enough to get them through the year."
Any questions?
Minding
With these kinds of little guys, once you see their cash situation you don't need to look further. You already should know they don't have a profit and won't anytime soon. Their revenues were up a little; not impressively so they aren't making huge inroads with their products or marketing. We'll learn more about that in the CC tomorrow (at 11 I believe).
The 10K and 10Qs are almost irrelevant. We all know what we need to know and don't know. The question is: Will we know after the CC tomorrow or will Nasrat punt?
Kind regards,
Minding
No $$$$ ... or there's enough to get them through the year.
The bigger question is, did you see anything new in it? I didn't but perhaps I missed something.
Kind regards,
Minding
Yeh, they gave him the shares.
Minding
Am I reading this correctly? The interim who had 50K shares just added 1M?
http://www.streetinsider.com/SEC+Filings/Form+4+CESCA+THERAPEUTICS+INC.+For%3A+Jun+09+Filed+by%3A+STRACEY+ROBIN+C/10646512.html
Kind regards,
Minding
That's a most reasonable measure, using market cap, for a company like Cocrystal. It's what I use also and I appreciate the reminder.
How would one know if 817M is a crazy market cap? I don't have a good comparison (and Yahoo is no help), but that's what I would look for -- the market caps of companies doing similar work and at a similar stage.
Kind regards,
Minding
NovaBay Pharmaceuticals, Inc. Analyst Rating Update
From http://thedailyrover.com/novabay-pharmaceuticals-inc-analyst-rating-update/
June 10, 2015 A+A-SHARE ON EMAILEMAILSHARE ON PRINTPRINT
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY): The Company shares has received a rating of Buy from 3 Wall Street Analysts. NovaBay Pharmaceuticals, Inc. shares have received a Mean Price Target of $1.72. According to the rating issued from 3 Wall Street Analysts, the High Price Target is seen at $2 while the Lower end of the Price Target is seen at $1.25. The Median Price Target is calculated at $1.9.
Many Wall Street Brokerage firms have commented on company shares. Maxim Group initiates coverage on NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY). In the latest research report, Maxim Group announces the target price to $2 per share on the counter. According to the latest information available, the shares are now rated Buy by the analysts at the agency.
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) witnessed a decline in the market cap on Tuesday as its shares dropped 1.76% or 0.0154 points. After the session commenced at $0.9, the stock reached the higher end at $0.9 while it hit a low of $0.84. With the volume soaring to 360,793 shares, the last trade was called at $0.86. The company has a 52-week high of $1.3. The company has a market cap of $53 million and there are 61,198,000 shares in outstanding. The 52-week low of the share price is $0.42. The Company has disclosed insider buying and selling activities to the Securities Exchange, The Securities and Exchange Commission has divulged in a Form 4 filing that the director of Novabay Pharmaceuticals, Inc., Sieczkarek Mark M had purchased shares worth of $100,000 in a transaction dated on March 3, 2015. A total of 166,666 shares were purchased at a price of $0.6 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Couch, we've had a few reasonable exchanges. I would think by now you would know I don't post 'negative' information on ELTP. You know I also don't post opinions based on hearsay, rumors, hopes, and dreams.
I have money in the stock. I expect to make money off the stock.
I have also concluded it is undervalued at the moment and, short of conspiracy theories about shorts, no one has explained to my satisfaction why it is so undervalued. My conclusion is that the market of shareholders and potential shareholders (which is a far greater number than the few people repetitively posting their hopes here) have a very different understanding of the situation than the iHub posters.
Kind regards,
Minding